Clinical Trial Update: A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II trial investigating Fruquintinib as third-line treatment for advanced pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Fudan University | Conditions: Advanced Pancreatic Carcinoma | Phase 2 | Status: UNKNOWN